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Background: Syntaxin 1 (STX1) is a presynaptic plasma membrane protein that coordinates synaptic vesicle
fusion. STX1 also regulates the function of neurotransmitter transporters, including the dopamine (DA) trans-
porter (DAT). The DAT is a membrane protein that controls DA homeostasis through the high-afﬁnity
re-uptake of synaptically released DA.
Methods:We adopt newly developed animal models and state-of-the-art biophysical techniques to determine
the contribution of the identiﬁed gene variants to impairments in DA neurotransmission observed in autism
spectrum disorder (ASD).
Outcomes:Here, we characterize two independent autism-associated variants in the genes that encode STX1 and
the DAT.We demonstrate that each variant dramatically alters DAT function.We identifymolecularmechanisms
that converge to inhibit reverse transport of DA and DA-associated behaviors. These mechanisms involve
decreased phosphorylation of STX1 at Ser14 mediated by casein kinase 2 as well as a reduction in STX1/DAT
interaction. These ﬁndings point to STX1/DAT interactions and STX1 phosphorylation as key regulators of DA
homeostasis.
Interpretation:We determine the molecular identity and the impact of these variants with the intent of deﬁning
DA dysfunction and associated behaviors as possible complications of ASD.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Autism spectrum disorder (ASD) is deﬁned by deﬁcits in social
communication and by the presence of restricted and repetitive
behaviors, which are often the ﬁrst signs of ASD (Rowberry et al.,nderbilt University School of
48, United States.
eger),
o.galli@vanderbilt.edu (A. Galli).
k.
. This is an open access article under2015; Wolff et al., 2014). Increased striatal size is among the most
consistent neuroimaging ﬁndings in ASD, and increased size and
growth of the striatum, a dopamine (DA) enriched brain region, have
been associated with severity of repetitive behaviors (Langen et al.,
2007, 2009, 2014; Hollander et al., 2005). Consistent with the in-
volvement of striatal dysfunction in ASD, recent studies have found
that individuals with ASD display diminished response to reward
(Dichter et al., 2012; Damiano et al., 2012; Lin et al., 2012) which
stems from striatal hypofunction (Kohls et al., 2013, 2014). Striatal
DA input has important roles in reward, movement, and habit (Zald
et al., 2004; Howe et al., 2011, 2013). Importantly, excessive striatalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Petrovic, 2010).
The DA transporter (DAT) shapes striatal DA signaling via re-uptake
of synaptically released DA (Kristensen et al., 2011). In addition to
its role in vesicular fusion, the plasma membrane protein syntaxin
1 (STX1) plays a pivotal role in regulating DAT functions (Binda et al.,
2008), and it has been observed to regulate other neurotransmitters:
sodium symporters (NSS) (Quick, 2002, 2003, 2006; Dipace et al.,
2007). Therefore, at the dopaminergic synapse, in addition to synaptic
release, the actions of STX1may regulate DAT functions and, as a conse-
quence, DA neurotransmission and associated behaviors.
ASD is associated with variants in several genes of the DA network,
including those encoding STX1 (Nakamura et al., 2008, 2011;
Durdiakova et al., 2014), the DAT (Hamilton et al., 2013; Bowton et al.,
2014), DA receptors, as well as enzymes involved in DA metabolism
(Hettinger et al., 2012; Qian et al., 2013; Reiersen and Todorov, 2011;
Yoo et al., 2013; Nguyen et al., 2014). Altered gene expression of
STX1A has also been described in post-mortem brain and in lympho-
cytes from people with ASD (Nakamura et al., 2008, 2011). These data
point to DA dysfunction as a potential complication and possible risk
factor for ASD, but without a clear understanding of the underlying
mechanisms.
Here,we have identiﬁed rare, inherited, functionalmissense variants
in the gene that encodes STX1 (STX1A; resulting in an Arg to Gln substi-
tution at site 26) and in the gene that encodes DAT (SLC6A3; resulting in
an Arg to Trp substitution at site 51) in separate individuals with ASD.
Among the different DAT functions, reverse transport of DA has
emerged as a contributing factor in DA neurotransmission and remains
incompletely understood (Leviel, 2011). Both of these variants disrupt
the molecular mechanisms of reverse transport of DA, resulting in DA
dysfunction and associated behavioral abnormalities. To mechanisti-
cally characterize these variants, we identify novel molecular events
involved in the STX1 regulation of DAT. Our results suggest a coordi-
nated molecular network, including STX1 and DAT that might con-
tribute to disruption of dopaminergic signaling in individual with
ASD.
2. Materials and Methods
All human subjects provided informed consent and the research
was approved by institutional human subjects boards. All experi-
ments, procedures, and surgeries involving mice were performed in
compliance with and were approved by the Institutional Animal Care
and Use Committee of Vanderbilt University.
2.1. Subjects and Clinical Assessment
All ASD cases were ascertained using the Autism Diagnostic
Interview—Revised (ADIR), the Autism Diagnostic Observation
Schedule—Generic (ADOS), and the DSM-IV diagnosis of pervasive
developmental disorder (Neale et al., 2012; Lim et al., 2013; Liu
et al., 2013). Clinical assessment of families harboring either variant
is dependent on which collection they belong to. In brief, families
that contain the SLC6A3 R/W or STX1A R/Q variant belong to the
Autism Sequencing Consortium (ASC) and the Simons Simplex
Collection (SSC) respectively, and have been previously reported
(Neale et al., 2012; De Rubeis et al., 2014; Iossifov et al., 2014).
ADIR is an extensive, semi-structured parent/guardian interview
that queries both historical and current information on the develop-
ment, behavior, and skills of a child. The ADOS is a structured observa-
tional assessment administered directly to participants. It is employed
to conﬁrm behaviors reported on the ADIR and consists of modules
adapted for differing language abilities. When used together, the ADIR
and ADOS are deemed the “gold-standard” instruments for validating
and ASD diagnosis.2.2. SLC6A3 R/W and STX1A R/Q Discovery and Validation
Methodological details on SLC6A3 R/W and STX1A R/Q discovery are
published (Neale et al., 2012; De Rubeis et al., 2014; Iossifov et al., 2014)
and validation of the variant was performed as described in Bowton
et al. (2014). DNAderived from both parents, the probands, and siblings
were subjected to sequence analysis. In all instances, each variant was
predicted to be heterozygous at their respective site and experimentally
validated and conﬁrmed via Sanger sequencing.
2.3. Cell Culture and Transfection
STX1 constructs in the pcDNA3.1(−) expression vector and the GFP-
hDAT-pCIHygro expression vectors containing hDAT or hDAT R/W
(Arg51 to Trp) sequence were generated, conﬁrmed and transiently
transfected into Chinese hamster ovary (CHO) cells. In some experi-
ments (noted in ﬁgure legend), stably transfected hDAT CHO cells
were used. These cells were generated as described in Bowton et al.
(2010). Cells were maintained in a 5% CO2 incubator at 37 °C andmain-
tained in Ham's F-12 medium supplemented with 10% fetal bovine
serum (FBS), 1 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL
streptomycin. Stably transfected hDAT CHO cells were kept under selec-
tion with 250 μg/mL hygromycin B (Corning Cellgro). Fugene-6 (Roche
Molecular Biochemicals) in serum-freemediawasused to transfect cells
using a 6:1 transfection reagent:DNA ratio. Assays were conducted
24–48 h post-transfection.
2.4. Superior Cervical Ganglion Neuron Culture and Transfection
SCG neurons were cultured from 1 to 3 day old male mouse pups.
SCGs were dissected in complete Ultraculture medium (Lonza) supple-
mented with 20 ng/mL nerve growth factor (NGF). SCGs were washed
with PBS and incubated for 20 min in collagenase (3%) and trypsin
(2.5%) at 37 °C. They were washed in complete Ultraculture medium
withNGF. Dissociated cellswere obtained by SCG trituration inmedium.
Cells were plated on poly-D-lysine coated MatTek® dish treated with
collagen (type IV). 24 h post-plating, the media was replaced with
Ultraculture medium with NGF and 10 μM 5-ﬂuoro-2-deoxyuridine
(FDU). SCGs were transfected via intranuclear microinjection of DNA.
2.5. Cell Surface Biotinylation and Protein Immunoblot
Cells were cultured in 6-well plates. For cell surface biotinylation
assays, cells were labeled with sulfo-NHS-SS-biotin (1.0 mg/mL; Pierce)
before puriﬁcation and analysis via SDS-PAGE/immunoblots. hDAT was
detected using a rat monoclonal primary antibody to the N-terminus of
hDAT (1:1000) (Millipore Bioscience Research Reagents, catalog num-
ber MAB369) and a goat-anti-rat-HRP-conjugated secondary antibody
(1:5000) (Jackson ImmunoResearch, catalog number sc-2006). The
phosphorylation level of STX1 at Ser14wasdetected using a rabbit poly-
clonal antibody against phospho-S14 either fromCastillo et al. (2010) or
with a commercially available antibody (1:2500) (Abcam, catalog
number ab63571) and with a goat-anti-rabbit-HRP-conjugated sec-
ondary antibody (1:5000) (Jackson ImmunoResearch, catalog num-
ber sc-3837). Total STX1 was detected using a mouse monoclonal
antibody (1:5000) (Sigma, catalog number S 0664) and a goat-
anti-mouse-HRP-conjugated secondary antibody (1:5000) (Jackson
ImmunoResearch, catalog number sc-2005).
2.6. Immunostaining
SCG neurons (at least 14 days in culture) were serum starved for 1 h
in DMEM:F12 and treated with vehicle or AMPH for 20 min. Neurons
were subsequently ﬁxed with PBS plus Ca2+/Mg2+ and 4% paraformal-
dehyde, washed three times with PBS plus Ca2+/Mg2+, permeabilized
and blocked with PBS with 4% bovine serum albumin (BSA)/0.15%
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in PBS plus 4% BSA and 0.05% Tween 20. NET was detected using a
mouse monoclonal antibody (1:5000) (Mab Technologies; NET05-2)
and p-STX1 with an afﬁnity puriﬁed rabbit polyclonal (1:1000),
anti-pSTX at Ser14 (Castillo et al., 2010). Primary antibodies were
visualized with the appropriate Alexa-labeled secondary antibody
from Invitrogen.
Mouse brain slices were prepared as outlined in the High Speed
Chronoamperometry section, except recovery was in aCSF for 1 h at
37 °C. Slices were ﬁxed, permeabilized,washed, and blocked as outlined
above. DATwas visualized using ratmonoclonal against DAT and STX1A
and STX1B were detected using rabbit polyclonal antiserum from SYSY.
p-STX at Ser14 was detected using an afﬁnity puriﬁed rabbit polyclon-
al(1:1000) (Castillo et al., 2010). Primary antibodies were visualized
with the appropriate covalently Alexa-labeled secondary antibody
from Invitrogen.
Immunoﬂuorescencewas imaged by capturing Z-series using a Zeiss
using a 63×Plan-APOCHROMAT oil lens (Vanderbilt University Medical
Center Cell Imaging Shared Resource). All images shown are from single
confocal sections, and image processing was performed using ImageJ
and Adobe Photoshop.2.7. Co-immunoprecipitations
Cells were grown to conﬂuence in 25 cm2 culture ﬂasks and serum
deprived for 1 h prior to assay. Cells were washed three times with 4
°C phosphate-buffered saline (Gibco) containing 1 mM EGTA and
1 mM EDTA, and then lysed in RIPA buffer (100 mM NaCl, 1.0% IGEPAL
CA-630 (NP-40), 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris,
pH = 7.4, supplemented with a protease inhibitor cocktail (Sigma)).
Lysateswere passed twice through a 27.5 gauge needle, and centrifuged
at 15,000 ×g for 30min.With a portion of the total cell lysate (TCL) col-
lected to run as the totals, 1 mL of the remaining supernatant was incu-
bated at 4 °C for 4 h with Sepharose-G beads (Fisher Scientiﬁc),
previously washed with 1% BSA in RIPA buffer, and then preincubated
with 2.5 μg DAT antibody (rat monoclonal, #MAB369, Millipore). For
the control, supernatant was incubated with BSA-blocked Sepharose-
G beads alone (no DAT antibody). After the 4-hour incubation, beads
were spun down, washed with cold RIPA buffer, and eluted with
Laemmli sample buffer at 37 °C for 30 min. TCL and bead eluates were
analyzed by SDS-PAGE (10%) and immunoblotted for total STX1 and
DAT. Band intensity was quantiﬁed using ImageJ software (National
Institutes of Health).2.8. Expression and Puriﬁcation of STX1
The cDNAs encoding STX, STX S14D and STX S14A lacking the trans-
membrane domain (STXΔTM, STX1ΔTM S14A and STX1ΔTM S14D)
were inserted into the bacterial expression vector pGEX, thereby adding
an N-terminal GST-tag followed by a thrombin cleavage site. The
resulting fusion proteins were produced in Escherichia coli BL21 DE3
LysS. The culture was grown at 30 °C to OD 0.8 and expression was in-
duced with 1 mM isopropylβ-D-1-thiogalactopyranoside at 30 °C, and
the culturewas harvested 4 h after induction. The frozen pelleted bacte-
riawere lyzed in buffer (PBS, 0.1% TX-100, 20 μg/mLDNAse I, 1mMDTT,
mix protease inhibitor (GE Healthcare)). The lysate was cleared by cen-
trifugation followed by incubation with 100 μL glutathione sepharose
beads (GE Healthcare, Uppsala, Sweden) at 4 °C for 1.5 h. The beads
were pelleted at 3000 rpm for 5 min and washed 3 times in buffer
(PBS, 0.1% TX-100, 1 mM DTT) before elution by cleavage with 1 μL
thrombin (GE Healthcare, Uppsala, Sweden) O/N at 4 °C. PMSF
(1 mM) was added, and the beads were ﬁltered through a P200 tip.
The concentration of the puriﬁed STX1B was measured by BCA assay
(Thermo Fisher Scientiﬁc, Waltham, MA).2.9. GST Pull-Down Assay
A DAT GST fusion protein containing the 64 N-terminal residues of
the transporter (GST hDAT 1–64)was expressed and bound to glutathi-
one sepharose beads as described (Binda et al., 2008). For the pull-
down, 20 μL beadswith either GST or GST hDAT 1–64 boundwere incu-
bated with 2 μg of puriﬁed STXΔTM, STX1ΔTM S14A or STX1ΔTM S14D
in 500 μL buffer (PBS, 0.1% TX-100, 0.1% BSA) for 30 min at 4 °C and
washed three times in buffer without BSA. Bound protein was eluted
by incubation of beads for 1 h at room temperature with 1 μL thrombin
in 15 μL buffer (PBS, 0.1% TX-100) followed by addition of SDS loading
buffer + 100 mM DTT and incubation for 25 min at 70 °C. Each sample
was split in two and loaded in two different Any-kD precast gels
(BioRad, Hercules, CA). One gelwas used as a Coomassie loading control
and the other was transfered to a PDVF membrane and immunoblotted
with primary mouse STX1 antibody (Sigma Aldrich. St. Louis, MO)
1:1000 and anti-mouse HRP-conjugated secondary antibody (Thermo
Fisher Scientiﬁc, Waltham, MA) 1:5000.
2.10. Amperometry
Cells were plated at a density of ~20,000 per 35-mm culture dish. To
load cells with DA, dishes werewashedwith KRH assay buffer (130mM
NaCl, 1.3 mM KCl, 1.2 mM KH2PO4, 10 mM HEPES, and 2.2 mM CaCl2,
pH 7.4) containing 10mMdextrose, 100 μMpargyline, 1mM tropolone,
and 100 μM ascorbic acid, and incubated with 1 μM DA in KRH assay
buffer for 20min at 37 °C. To preload SCG neurons, dishes were washed
with KRH assay buffer (as above) containing 100 nM raclopride. Dishes
were washed three times with the external bath solution (130 mM
NaCl, 10 mM HEPES, 34 mM dextrose, 1.5 mM CaCl2, 0.5 mM MgSO4,
1.3 mM KH2PO4, adjusted pH to 7.35, and 300 mOsm). A carbon ﬁber
electrode (ProCFE; ﬁber diameter of 5 μm; obtained from Dagan Corpo-
ration) juxtaposed to the plasma membrane and held at +700 mV
(a potential greater than the oxidation potential of DA) was used to
measure DA ﬂux through oxidation reactions. Amperometric currents
in response to the addition of 10 μM AMPH were recorded using an
Axopatch 200B ampliﬁer (Molecular Devices, Union City, CA) with a
low-pass Bessel ﬁlter set at 1 kHz; traces were digitally ﬁltered ofﬂine
at 1 Hz using Clampex9 software (Molecular Devices, Union City, CA).
DA efﬂuxwas quantiﬁed as the peak value of the amperometric current
for all experiments except for recordings from SCG neurons. For SCG
neurons, total DA efﬂux was quantiﬁed as the integral of the trace for
a ﬁxed 15-minute window.
2.11. High Speed Chronoamperometry
Striatal hemislices (300 μm) from 6 to 10 week old C57BL/6 mice
were preparedwith a vibratome (Leica VT1000S) in an ice cold oxygen-
ated (95% O2/5% CO2) sucrose cutting solution consisting of (in mM):
210 sucrose, 20 NaCl, 2.5 KCl, 1 MgCl2, 1.2 NaH2PO4, 10 glucose, 26
NaHCO3. Slices were then transferred to oxygenated artiﬁcial cerebro-
spinal ﬂuid (aCSF) at 28 °C for a minimum of 1 h. The aCSF consisted
of (inmM): 125NaCl, 2.5 KCl, 1MgCl2, 2 CaCl2, 1.2 NaH2PO4, 10 glucose,
26NaHCO3, 0.25 ascorbic acid. Striatal sliceswere treated at 37 °C for 1 h
with either 100 nM BONT/C or vehicle control. DA concentration was
measured by chronoamperometry in striatal slices. Brieﬂy, carbon
ﬁber electrodes (100 μm length × 30 μm O.D.) coated with naﬁon for
DA selectivity were lowered into the desired recording site or sites so
that the tip of the recording electrode was positioned at a depth of
75–100 μm. The voltage was stepped from 0 mV to 550 mV for
100 ms and then back to 0 mV and the charging current of the carbon
ﬁber electrode was allowed to decay for 20 msec before the signals
were integrated. Data were collected at a frequency of 1 Hz with an
Axopatch 200B ampliﬁer. The integrated charge was converted to DA
concentration based on in vitro calibration with DA.
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For DA uptake in a heterologous expression system: cells were
plated on poly-D-lysine coated, 24-well plates and grown to ~90% con-
ﬂuence. On the day of the experiment, cells were washed with 37 °C
KRH buffer containing 10 mM dextrose, 100 μM pargyline, 1 mM
tropolone, and 100 μM ascorbic acid, and equilibrated for 5 min at 37
°C. Saturation kinetics of DA uptake was determined using a mixture
of [3H]DA (PerkinElmer Life Sciences, Waltham, MA) and unlabeled
DA (Sigma Aldrich) diluting to ﬁnal DA concentrations of 0.05 μM–
10 μM. Uptake was initiated by bath addition of the dilution row mix-
ture. Uptake was terminated after 10 min by washing twice in ice-cold
KRH buffer. Scintillation ﬂuid (Optiphase HiSafe 3, PerkinElmer Life Sci-
ences) was added to the wells and the plates were counted in a Wallac
Tri-Lux β-scintillation counter (Wallac). Nonspeciﬁc bindingwas deter-
mined in the presence of 10 μM cocaine. Km and Vmax values were de-
rived by ﬁtting Michaelis–Menten kinetics to the background
corrected uptake data, using GraphPad Prism 5.0 (GraphPad Software,
San Diego, CA). All determinations were performed in triplicates.
For DA uptake in striatal slices: striatal hemislices (prepared as pre-
viously mentioned) were treated at 37 °C for 1 h with either 100 nM
BONT/C or vehicle control. Slices were then exposed to 50 nM [3H]DA
for 10 min. DAT-speciﬁc DA uptake was determined by subtracting
the non-speciﬁc signal in the presence of 3 μM GBR12909. At the end
of the [3H]DA treatment, the slices were washed with cold aCSF and
the striatum dissected. Tissue samples were then homogenized in
200 μL of lysis buffer consisting of 150 mM NaCl, 25 mM HEPES, 2 mM
sodium orthovanadate, 2 mM sodium ﬂuoride, 1% Triton-100. The
homogenate was centrifuged at 13,000 ×g at 4 °C for 30 min and the
supernatant added to 500 μL of buffer 150 mM NaCl, 25 mM HEPES,
2 mM sodium orthovanadate, 2 mM sodium ﬂuoride, 0.1% Triton-100.
The protein concentration of each sample was measured and 500 μL of
each sample was added to scintillation vials to count [3H]DA. Counts
were expressed as a ratio to protein content and normalized to the
mean value for the control condition within each experiment.
For DA uptake in dissected Drosophila brains: 2–5 day old males
were collected, anesthetized with CO2, and brains were dissected in
Schneider's medium (GIBCO) with 1.5% BSA. The retina was removed,
and four brains per condition were pooled in Millipore Millicell inserts
in 24 well plates. Brains were washed with Schneider's medium, then
washed in a standard ﬂy saline solution (HL3) plus 1.5% BSA and
10 mMMgSO4. For 15 min at room temperature, brains were exposed
to 200 nM [3H]DA in HL3 plus 1.5% BSA and 115 μMascorbic acid. Brains
were then washed six times with 1.4 mL HL3 plus 1.5% BSA at 4 °C.
Brains were placed into scintillation vials in 100 μL 0.1% SDS. Scintilla-
tion ﬂuid was added to count [3H]DA.
2.13. Drosophila Genetics, Molecular Biology, and Construction of UAS
hDAT
Flies lacking the Drosophila dopamine transporter (DATfmn) (Kume
et al., 2005) and ﬂies harboring TH-Gal4 were outcrossed to a control
line (Bloomington Indiana (BI) 6326) and selected by PCR or by eye
color. TH-GAL4 (Bl 8848) and M{vas-int.Dm}ZH-2A, M{3xP3-RFP.attP
′} ZH-22A (Bl 24481) were obtained from the BI stock center and
outcrossed to ﬂies lacking the Drosophila DAT (DATfmn) and carrying
the white (w1118) mutation (BI stock number 6236) for 5–10 genera-
tions. Transgenes (hDAT or hDAT R/W) were cloned into pBI-UASC,
and constructs were injected into embryos from M{vas-int.Dm}ZH-2A,
M{3xP3-RFP.attP′}ZH-22A (Bl 24481). Initial potential transformants
were isolated by selecting for red eyes and lack of GFP signal in the
head. Transformants were also veriﬁed by RFP ﬂuorescence and
outcrossed 5–8 times to DATfmn ﬂies. The presence of DATfmn lesion
was veriﬁed by PCR. To generate CK2-DN ﬂies, we drove the expression
of a severely functionally compromised dominant negative version of
CK2α (UAS-Tik) (Bose et al., 2006) in dopaminergic neurons by usingTH-Gal4. UAS-Tik is based on a CK2α allele (Tik) that in a heterozygous
condition, causes no obvious neural abnormalities (Lin et al., 2002). Tik
has two substitutions, M161K and E165D. M161K is in the ATP-binding
pocket preventing nucleotide-binding thereby eliminating catalytic
activity (Lin et al., 2002; Rasmussen et al., 2005). Overexpression from
the UAS-Tik construct to dominantly blocks CK2 function (Bose et al.,
2006). Therefore, UAS-Tik can be used as a CK2-DN construct. Flies
were maintained on a standard cornmeal/molasses/yeast media at 25
°C and 65% humidity with a 12 hour/12 hour light/dark cycle. Lights
came on at 8 AM and off at 8 PM.
2.14. Behavioral Analysis
Three day old males were collected and placed into tubes with food
for three days. After three days locomotion was recorded for 32 h by
beam breaks and analyzed using equipment/software from Trikinetics
(www.trikinetics.com). For the AMPH-induced locomotion, males
were starved for 6 h and then fed sucrose (10 mM) containing either
AMPH (1 mM) or vehicle.
2.15. Statistical Analysis
Compiled data are expressed as normalizedmean± s.e.m. For statis-
tical analysis, we used either a Student's t-test or ANOVA depending on
the n of the experimental groups. p b 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Autism-Related hDAT and STX1 Variants Alter DA Transport
Exome capture and sequencing analysis identiﬁed two families har-
boring separate rare and inherited SNPs. One family harbors a single nu-
cleotide variant (SNV) in the gene that encodes hDAT (SLC6A3; resulting
in an Arg to Trp substitution at site 51; hDAT R/W) (Fig. 1A, left panel).
The other family harbors a SNV in the gene that encodes STX1A (STX1A;
resulting in an Arg to Gln substitution at site 26; STX1 R/Q) (Fig. 1A,
right panel). Neither of these SNVs were found in control samples
(n = 1463) and were not deposited in the NHLBI Exome Sequencing
Project (URL: http://evs.gs.washington.edu/EVS/) [3 (November,
2014) accessed].
The family harboring the STX1A R/Q variant is in a cohort of families
belonging to the Simons Simplex Collection (SSC), a well-characterized
ASD collection. The family harboring the SLC6A3 R/W variant is in the
cohort of families studied by the Autism Sequencing Consortium
(ASC). Details on ASC samples and characteristics have been previously
published (Neale et al., 2012). The ADIR scores are presented in table
format in supplemental materials (Supp. Table 1). Thus, we are classify-
ing these variants as ASD-speciﬁc. The hDAT Arg51 is located at the N-
terminus in a region highly conserved across multiple species
(Fig. 1B). STX1A Arg26 is located at the N-terminus and is also con-
served across several species as well as in other STX1 isoforms, includ-
ing STX1B (Fig. 1C). The two redundant neuronaThil STX1 isoforms
(STX1A and STX1B) are 84% identical. Both isoforms are present in DA
neurons and striatal DA terminals and colocalize with DAT (Supp.
Fig. 1). In this study we utilize STX1B, here simply referred as STX1.
To evaluatewhether the STX1 R/Q variant promotes DAdysfunction,
we determined the impact of this variant on a key STX1 regulatory site
(Ser14) implicated in neuropsychiatric disorders (Castillo et al., 2010)
and hDAT function. hDAT cells (see Methods) expressing STX1 R/Q
show reduced STX1 phosphorylation at Ser14 (Fig. 2A). One function
of STX1 is to regulate the DAT-mediated reverse transport of DA in
response to AMPH (Binda et al., 2008). Therefore, we used AMPH as a
tool to probe whether STX1 R/Q has an altered ability to regulate DA
efﬂux, measured by amperometry in hDAT cells. The amperometric
probe, a carbon ﬁber electrode juxtaposed to the cell membrane,
Fig. 1. Pedigree and cross-species conservation of hDAT R/W and STX1 R/Q. (A) Variant inheritance is shown for the families harboring the hDAT R/W and the STX1 R/Q genotypes. Filled
symbols indicate individuals with an ASD diagnosis, while open symbols reﬂect individuals without an ASD diagnosis. (B) Alignment of the DAT amino acid sequence across multiple spe-
cies. Arginine 51 is represented in red. (C) Alignment of the STX1 amino acid sequence across isoforms and multiple species. Arginine 25 is represented in red.
139E. Cartier et al. / EBioMedicine 2 (2015) 135–146measures DA efﬂux by oxidation/reduction reactions, with DA efﬂux
represented as a positive current. hDAT cells expressing STX1 R/Q dis-
play a signiﬁcantly reduced AMPH-induced DA efﬂux as compared to
hDAT cells expressing STX1 (Fig. 2B). It is important to point out that
in hDAT cells expressing STX1 R/Q, the Vmax of DA uptake was signiﬁ-
cantly increased, whereas the Km of DA was not signiﬁcantly different
from that of hDAT cells expressing STX1 (Fig. 2C, top). A representative
plot of DA uptake kinetics is shown in Fig. 2C (bottom). These data indi-
cate that the STX1 R/Q variant asymmetrically regulates hDAT function
by selectively impairing DA efﬂux.
In order to determine whether other ASD-associated variants can
disrupt DAT function by parallel mechanisms to those of STX1, weFig. 2. STX1 R to Qmissense variant decreases STX1 phosphorylation and reverse transport of D
STX1 or STX1 R/Q were immunoblotted with a phospho-speciﬁc antibody directed against STX
non-speciﬁc binding. Bottom lane shows total STX1 proteins. Bottom: quantitation of band inten
a percentage STX1 (** = p b 0.01 by Student's t-test; n = 5, in triplicate). (B) Top: representati
STX1 or STX1 R/Q. Arrows indicate application of 10 μM AMPH. Bottom: quantitation of AMPH
percent of the current recorded in hDAT cells expressing STX1 (* = p b 0.05 by Student's t-t
(Vmax and Km) for stably transfected hDAT cells expressing either STX1 or STX1 R/Q (Vmax: p b 0
licate). Bottom: representative plot of [3H]DAuptake kinetics in stably transfectedhDAT cells exp
way ANOVA followed by Bonferroni post-test; in triplicate).explored changes in hDAT function in cells expressing hDAT R/W. The
AMPH-induced reverse transport of DA was reduced in hDAT R/W
cells with respect to hDAT cells (Fig. 3A). These data parallel the reduc-
tion in DAefﬂux observed in hDAT cells expressing the STX1 R/Q variant
(Fig. 2B). This reduction in AMPH-induced DA efﬂux in the hDAT R/W is
not mirrored by a signiﬁcant reduction in DA uptake or DA apparent af-
ﬁnity (Fig. 3B), indicating the hDAT R/W variant also asymmetrically
regulates hDAT function by selectively impairing DA efﬂux.
Previously, we determined that reverse transport of DA induced
by AMPH is tightly regulated by the interaction of STX1 at the DAT
N-terminus (Binda et al., 2008). Therefore, we explored whether the
reduced reverse transport of DA in hDAT R/W cells stemmed from aAwithout decreasing DA uptake: (A) Top: stably transfected hDAT cells expressing either
1 at Ser14 (top lane). The mock transfection of GFP alone (mock) supports the absence of
sities of phospho-STX1 (p-STX1) normalized to the respective total STX1 and expressed as
ve AMPH-induced DA efﬂux recorded from stably transfected hDAT cells expressing either
-induced DA efﬂux. Data are represented as maximal amperometric current expressed as
est; n = 7). (C) STX1 R/Q enhances DAT-mediated DA uptake. Top: kinetic parameters
.05 by Student's t-test; n= 3, in triplicate; Km: p N 0.46 by Student's t-test; n= 3, in trip-
ressing STX1 (ﬁlled squares) and STX1 R/Q (empty squares) cells (***=p b 0.001, by two-
Fig. 3. hDAT R toWmissense variant has decreased STX1 association, reduced reverse transport of DA, but normal DA uptake: (A) Top: representative AMPH-induced DA efﬂux recorded
from hDAT or hDAT R/W cells expressing STX1. Arrows indicate application of 10 μM AMPH. Bottom: quantitation of AMPH-induced DA efﬂux. Data are represented as maximal current
expressed as percent of the current recorded in hDAT cells (* = p b 0.05 by Student's t-test; n= 5). (B) hDAT R/W exhibits normal DA uptake function. Top: kinetic parameters (Vmax and
Km) for hDAT and hDAT R/W (Vmax: p N 0.92 by Student's t-test; n = 3, in triplicate; Km: p N 0.62 by Student's t-test; n = 3, in triplicate). Bottom: representative plot of [3H]DA uptake
kinetics in hDAT (ﬁlled squares) and hDAT R/W (empty squares) cells (p N 0.05, by two-way ANOVA followed by Bonferroni post-test; in triplicate). (C) Top: hDAT immunoprecipitates
from either hDAT or hDAT R/W cells expressing STX1 were immunoblotted for STX1 (top lane). The beads fraction supports the absence of non-speciﬁc binding. Third lane shows an
immunoblot for total STX1 proteins. Bottom lane shows an immunoblot for total hDAT proteins. Bottom: quantitation of hDAT pull down band intensities normalized to the respective
total STX1 and total hDAT; expressed as a percentage hDAT cells (* = p b 0.05 by Student's t-test; n = 5).
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hDAT and immunoblotted the immunoprecipitates for STX1 (Fig. 3C).
The amount of STX1 recovered in the DAT immunoprecipitates was
reduced in the hDAT R/W cells compared to the hDAT cells (Fig. 3C,
IB: STX1). In the absence of antibody against DAT, no signal was
detected for STX1 in the immunoprecipitates (Fig. 3C, beads). The
total STX1 and hDAT in the hDAT R/W cells was not decreased with
respect to hDAT cells (Fig. 3C, total STX1 and total hDAT). These data
demonstrate that the hDAT R/W variant has a reduced STX1/DAT inter-
action. Quantitation of multiple experiments is shown in the bar graph
of Fig. 3C. These data highlight that the ASD-associated hDAT and
STX1 variants both impair reverse transport of DA without inhibiting
DAT-mediated DA uptake functions.Fig. 4. CK2-mediated phosphorylation of STX1 at S14 promotes STX1/DAT interaction: (A) Stab
TBB for 20 min. STX1 proteins were immunoblotted for p-STX1 (with a phospho-speciﬁc an
corresponding total STX1 band densities and expressed as a percentage of vehicle control. CK2
t-test; n = 4). (B) Stably transfected hDAT cells transfected with STX1 were treated with
immunoblotted for STX1 and DAT. STX1 band densities were normalized to DAT and expressed
action (* = p b 0.05 by Student's t-test; n = 4). (C) Stably transfected hDAT cells were tra
immunoblotted for either STX1 (top band) or hDAT (middle band). Input (bottomband) serves a
as a percentage of STX1. STX1 S14A displays a signiﬁcantly decreased association with DA
Test; n = 6). (D) Puriﬁed STX1ΔTM peptides (S14A or S14D) were incubated with a GST
alone. The samples were then immunoblotted for STX1. STX1 band densities were expressed a
N-terminus (* = p b 0.05 by Student's t-test; n = 5).3.2. STX1 Phosphorylation Regulates STX1/DAT Interaction
STX1 is phosphorylated at Ser14 by the kinase CK2 (Hirling and
Scheller, 1996; Foletti et al., 2000), a posttranslational modiﬁcation in-
volved in the functional regulation of STX1 (Khelashvili et al., 2012;
Dubois et al., 2002). Fig. 2A shows that the STX1 R/Q variant has reduced
phosphorylation at Ser14. Therefore, we sought to determine the func-
tional consequences of impaired Ser14 phosphorylation. First, we dem-
onstrated that the highly selective ATP/GTP-competitive inhibitor of
CK2, 4,5,6,7-tetrabromobenzotriazole (TBB, 10 μM), effectively reduces
p-STX1 in hDAT cells. p-STX1 levels were determined either upon TBB
treatment or control conditions with a phospho-speciﬁc antibody that
recognizes phosphorylation of Ser14 (Castillo et al., 2010) (Fig. 4A).ly transfected hDAT cells transfected with STX1 were treated with either vehicle or 10 μM
tibody directed against Ser14) and STX1. p-STX1 band densities were normalized to the
inhibition with TBB signiﬁcantly decreased the levels of p-STX1 (*= p b 0.05 by Student's
either vehicle or 10 μM TBB for 20 min. hDAT proteins were immunoprecipitated and
as a percentage of vehicle control. CK2 inhibition signiﬁcantly decreased STX1/DAT inter-
nsfected with either STX1, STX1 S14A, or STX1 S14D. hDAT immunoprecipitates were
s loading control. All STX1 isoformbanddensitieswere normalized to hDATandexpressed
T (* = p b 0.05 by one-way ANOVA followed by Newman–Keuls Multiple Comparison
fusion protein of the ﬁrst 64 amino acids of the hDAT N-terminus (N64) or with GST
s a percentage of STX1ΔTM S14D. STX1ΔTM S14A displays reduced binding to the hDAT
141E. Cartier et al. / EBioMedicine 2 (2015) 135–146TBB signiﬁcantly decreases basal levels of p-STX1, demonstrating that
CK2 regulates the phosphorylation state of STX1 at Ser14.
Next, we investigatedwhether STX1 phosphorylation at Ser14 regu-
lates the association of STX1with the DAT. hDAT cellswere treatedwith
either TBB (10 μM for 20 min) or vehicle control, and the cell lysates
were immunoprecipitated for DAT and subsequently immunoblotted
for STX1. Inhibition of STX1 phosphorylation with TBB reduces STX1/
DAT association (Fig. 4B), demonstrating that phosphorylation pro-
motes the STX1/DAT interaction. TBB (10 μM for 20min) did not change
the level of DAT available at the cell surface (hDAT surface expression
for TBB exposure was 89.0 ± 12.9% of vehicle control; p N 0.40 by
Student's t-test; n = 4), indicating that the reduced STX1/DAT interac-
tion following CK2 inhibition is not due to DAT trafﬁcking away from
the plasma membrane. Collectively, these results are consistent with a
coordinated signaling complex whereby phosphorylation of STX1 at
Ser14 promotes its association with DAT.
STX1 can be phosphorylated at residues other than Ser14. For exam-
ple, casein kinase 1 can promote STX1 phosphorylation at Thr21
(Dubois et al., 2002). Therefore, we validatedwhether the level of phos-
phorylation of Ser14 alone supports STX1/DAT interactions. We gener-
ated STX1 constructs that either prevent Ser14 phosphorylation, by
mutating Ser14 to Ala (STX1 S14A), or mimic Ser14 phosphorylation,
by mutating Ser14 to Asp (STX1 S14D). We performed immunoprecip-
itation experiments in hDAT cells transfected with the different STX1
constructs. We observed that the STX1/DAT association is blunted in
hDAT cells expressing STX1 S14A as compared to hDAT cells expressing
STX1 (Fig. 4C). Furthermore, the pseudo-phosphorylated STX1 S14D
exhibits increased interaction with hDAT with respect to STX1 S14A.
Thus, phosphorylation of STX1 at Ser14 supports STX1/DAT association.
Plasma membrane levels of hDAT, as measured by biotinylation, were
not altered by the expression of either STX1 S14A or STX1 S14D when
compared to STX1 (STX1 S14A: hDAT surface expression was 101 ±
39% and STX1 S14D: hDAT surface expression was 88 ± 16% relative
to hDAT cells expressing STX1; p N 0.89 by one-way ANOVA; n = 5–6).
To determine whether Ser14 phosphorylation regulates the direct
association between STX1 and DAT, we used an in vitro GST pull-
down assay modiﬁed from Binda et al. (2008), which previously dem-
onstrated that the hDAT N-terminus directly interacts with STX1
(Binda et al., 2008). GST hDAT N-terminal fusion proteins (hDAT N64,
see the Materials andMethods section) were used to pull down recom-
binant soluble constructs of STX1 lacking the transmembrane domain
(STX1ΔTM) with Ser14 mutated to Ala (STX1ΔTM S14A) or Asp
(STX1ΔTM S14D) (Fig. 4D). hDAT N64 robustly pulled down STX1ΔTM
S14D. However, hDAT N64 pull down of STX1ΔTM S14A was dramati-
cally blunted. GST alone did not pull down either STX1ΔTM construct.
Quantitative analysis of band densities in Fig. 4D demonstrates that
the STX1ΔTM S14A peptide exhibits a signiﬁcantly reduced direct asso-
ciationwith theDATN-terminus relative to the STX1ΔTMS14D peptide.
Input bands show that the STX1ΔTM constructs were of expected size
and exhibited minimal degradation. These data further support the
notion that STX1 phosphorylation at Ser14 is a key regulator of the
dynamic, direct interaction between STX1 and DAT.
3.3. STX1 Phosphorylation Supports Reverse Transport of DA
Fig. 2B shows that the STX1 R/Q variant promotes a reduction in DA
efﬂux. Therefore, it is possible that the CK2-mediated phosphorylation
of STX1 at Ser14 support reverse transport of DA. We ﬁrst determined
whether AMPH causes an increase in STX1 phosphorylation. To test
this, p-STX1 levels were measured in hDAT cells transfected with
STX1 and treated either with vehicle, AMPH, or AMPH in the presence
of TBB (Fig. 5A). AMPH treatment increased the level of p-STX1 with
respect to vehicle control. Pre-treatment of cells with TBB (10 μM for
20 min) prevented the AMPH-induced phosphorylation of STX1 at
Ser14, demonstrating that AMPH induces phosphorylation of STX1 in
a CK2-dependent manner. Quantitation of the band density of p-STX1,normalized to total STX1 and expressed as a percent of control is
shown in Fig. 5A (bottom).
These ﬁndings implicate CK2 and phosphorylation of STX1 at Ser14
as possible novel molecular mediators of reverse transport of DA.
Thus, we investigated the role of CK2 function and STX1 phosphoryla-
tion at Ser14 in AMPH-induced DA efﬂux. DA efﬂux was quantiﬁed by
amperometry in hDAT cells expressing STX1 under control conditions
or pharmacological inhibition of CK2 with TBB (10 μM for 20 min).
TBB reduced AMPH-induced DA efﬂux as compared to vehicle control
treated cells (Fig. 5B). These data support our hypothesis that STX1
phosphorylation at Ser14 regulates reverse transport of DA. To further
test this hypothesis, we determined if the ability of TBB to regulate DA
efﬂux is altered by preventing or mimicking phosphorylation of STX1.
We expressed STX1 S14A or STX1 S14D constructs in hDAT cells and
measured AMPH-induced DA efﬂux in the presence or absence of TBB.
In hDAT cells expressing STX1 S14A, AMPH-induced DA efﬂux was not
sensitive to pharmacological inhibition of CK2, and the absolute DA
efﬂux in vehicle control was comparable to hDAT cells expressing
STX1 that were TBB treated (Fig. 5C, compare to Fig. 5B TBB treated).
Further, in hDAT cells expressing STX1 S14D, AMPH-induced DA efﬂux
was also not sensitive to TBB. However, the absolute DA efﬂux in the
presence of TBB was comparable to vehicle treated hDAT cells express-
ing STX1 (Fig. 5D, compare to Fig. 5B vehicle treated). These results
demonstrate that preventing STX1 phosphorylation (STX1 S14A) paral-
lels pharmacological inhibition of CK2, and mimicking STX1 phosphor-
ylation (STX1 S14D) obscures the ability of TBB to inhibit DA efﬂux. It
also points to the phosphorylation state of STX1 at Ser14 as a deter-
mining factor in the magnitude of reverse transport of DA, further
supporting our hypothesis that the STX1 R/Q variant alters DA neu-
rotransmission via reduced phosphorylation.
Cultured catecholamine neurons from the superior cervical ganglion
(SCG) have large presynaptic boutons that are amenable to imaging
approaches, allowing us to determinewhether AMPHdrives STX1phos-
phorylation at these release sites. SCGneurons natively express theNET,
which has 66% amino acid sequence homology with the DAT, as well as
the accompanying catecholamine presynaptic machinery (Matthies
et al., 2009). Here, we utilized confocal imaging of SCG presynaptic
boutons coupled with immunoﬂuorescence to reveal the presence of
endogenous p-STX1, closely localized to the NET (Supp. Fig. 2A). Consis-
tent with our ﬁndings in hDAT cells (see Fig. 5A), AMPH treatment
(10 μMfor 20min) enhances STX1 phosphorylation at Ser14 in SCG pre-
synaptic terminals (Supp. Fig. 2B). SCG cultured neurons also express
endogenous CK2α (Supp. Fig. 2C). Lastly and notably, in mouse striatal
slices, there is a similar proﬁle of endogenous STX1 and p-STX1 expres-
sion. (Supp. Fig. 2D). These data present SCG neurons as a biologically
relevant preparation in which to observe the functional role of STX1 in
reverse transport of DA.
3.4. STX1 Phosphorylation Regulates Reverse Transport of DA at Neuronal
Release Sites
Next, we explored the role of STX1 phosphorylation in DAT-
mediated reverse transport of DA at the level of the SCG presynaptic
boutons. Since SCG neurons do not natively express DAT, we used neu-
rons cultured from NET knockout mice and transiently transfected with
hDAT labeled with a GFP tag (Fig. 6A, inset). GFP ﬂuorescence was used
to identify neurons positive for hDAT expression. AMPH-induced DA
efﬂux was recorded with amperometry from individual synaptic
boutons (Fig. 6A). This DA efﬂux was cocaine sensitive, indicating its
DAT dependence (data not shown). TBB (10 μM for 20 min) reduced
AMPH-induced DA release as compared to vehicle control (Fig. 6A).
These data demonstrate, at the level of a single bouton, that CK2
function and STX1 phosphorylation are critical mediators of AMPH-
induced DAT-mediated DA release.
We then determined the importance of STX1 for reverse transport of
DA in ex vivo preparations. In mouse striatal slices, pre-incubation in
Fig. 5. STX1 phosphorylation promotes reverse transport of DA: (A) Top: stably transfected hDAT cells expressing STX1were treatedwith either vehicle or 10 μMTBB for 20min. This was
followed by an additional treatment with vehicle or 10 μM AMPH for 15 min. STX1 immunoprecipitates were immunoblotted for either p-STX1 (Ser14) or STX1. Bottom: the
immunoprecipitated band densities were quantiﬁed, normalized to the corresponding density of total precipitated STX1, and expressed as a percentage of vehicle control (* = p b 0.05
by one-way ANOVA followed by Newman–Keuls Multiple Comparison Test; n = 3). (B) Representative AMPH-induced DA efﬂux recorded from stably transfected hDAT cells expressing
STX1 treatedwith either vehicle or 10 μMTBB for 20min just before the amperometric recordings. Arrows indicate application of 10 μMAMPH. Bottom: quantitation of AMPH-inducedDA
efﬂux. Data are represented as maximal oxidative current (* = p b 0.05 by Student's t-test; n = 5). (C) Representative AMPH-induced amperometric currents recorded from stably
transfected hDAT cells expressing STX1 S14A treatedwith either vehicle or 10 μMTBB for 20min. Arrows indicate application of 10 μMAMPH. Bottom: quantitation ofmaximal oxidative
current (p N 0.05 by Student's t-test; n= 4–7). (D) Representative AMPH-induced amperometric currents recorded from stably transfected hDAT cells expressing STX1 S14D treatedwith
either vehicle or 10 μMTBB for 20 min. Arrows indicate application of 10 μMAMPH. Bottom: quantitation of AMPH-induced DA efﬂux. Data are represented as maximal oxidative current
(p N 0.05 by Student's t-test; n = 6).
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known to cleave STX1, inhibits AMPH-induced DA efﬂux as measured
by high speed chronoamperometry (Fig. 6B). Importantly, this BoNT/C
pre-incubation paradigm was not effective in signiﬁcantly altering DA
uptake (Fig. 6C). These data demonstrate the pivotal role of STX1 in
supporting DA efﬂux without altering forward transport of DA in brain
tissues.
3.5. STX1 Phosphorylation and STX1/DAT Association Regulates
Dopaminergic Behaviors
In adult Drosophila males, we developed locomotor assays for an
in vivo examination of DAT-mediated reverse transport of DA and the
impact of ASD variants on this transport process. First, we explored
how impairments in STX1 phosphorylation, which affects STX1/DATassociations, regulate DA-associated behaviors. In Drosophila, locomo-
tion requires functional DA neurotransmission (Hamilton et al., 2013,
2014; Pizzo et al., 2013). To probe for changes in locomotion, adult
males were fed a sucrose solution containing either AMPH (1 mM) or
vehicle. We observed that AMPH signiﬁcantly stimulated locomotion
in wild-type (WT) Drosophila (Fig. 7A). However, AMPH did not signif-
icantly increase locomotion in ﬂies lacking dDAT (DAT KO) (Kume et al.,
2005), indicating that AMPH-induced locomotion is a DAT-dependent
behavior (Fig. 7A). These data strongly support this assay as a model
to test the multiple functions of DAT in vivo.
CK2 function promotes STX1 phosphorylation at Ser14, STX1/DAT
interaction, and reverse transport of DA. Thus, to probe the behavioral
signiﬁcance of impaired STX1 phosphorylation at Ser14 and STX1/DAT
interaction, we evaluated whether inhibited CK2 function alters
AMPH-induced locomotion. We expressed a dominant negative form
Fig. 6. Inhibition of STX1 phosphorylation or cleavage of STX1 inhibits DA efﬂux but not uptake: (A) Inset: Image of a single GFP-hDAT transfected SCG neuron; arrows indicate the site of
amperometric recording (i.e. the presynaptic bouton). Top: representative AMPH-induced amperometric currents recorded from a single presynaptic bouton of SCG neurons expressing
GFP-hDAT after treatment with either vehicle or 10 μMTBB for 20 min. Bottom: quantitation of the maximal oxidative current normalized to vehicle treatment (*= p b 0.05 by Student's
t-test; n=5). (B) AMPH (10 μM)-inducedDAefﬂux recorded inmouse striatal slices preincubated (1 h) eitherwith vehicle or BoNT/C (100nM) (*=p b 0.05 by two-wayANOVA; n=6).
(C) [3H]DA uptake measure in striatal slices receiving identical treatment as in panel (c) (p N 0.05 by Student's t-test; n = 4).
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single copy CK2DN in a WT background, selectively in DA neurons.
We compared the AMPH-induced behavioral responses of ﬂies express-
ing CK2DN to WT ﬂies. AMPH did not signiﬁcantly increase locomotor
activity in ﬂies expressing dominant negative CK2mutant (Fig. 7B). Fur-
thermore, vehicle treatment did notmodify locomotion of ﬂies express-
ing CK2DN with respect to WT ﬂies, suggesting that extracellular DA
level did not change under basal conditions. Consistent with this, CK2
inhibition by TBB treatment (10 μM for 15min) did not alter DA uptake
in intact Drosophila brains (Fig. 7B, inset). Importantly, brains obtained
from dDAT KO ﬂies show robustly reduced DA uptake, demonstrating
the DAT dependence of DA uptake in our newly developed uptake
assay. Collectively, these data point to CK2 activity, STX1 phosphoryla-
tion at Ser14, and STX1/DAT association as critical mediators of reverse
transport of DA and associated behaviors.
Next, we explored how the ASD-associated hDAT R/W variant that
impairs STX1/DAT association affects DA-dependent behaviors in our
Drosophila model system. We expressed hDAT or hDAT R/W in DA
neurons of dDAT KO ﬂies as described above. We fed male Drosophila
a sucrose solution containing either AMPH (1 mM) or vehicle and
quantiﬁed locomotion in 30-minute intervals. AMPH exposure in-
duced a signiﬁcantly smaller increase in locomotion in hDAT R/Wexpressing ﬂies as compared to hDAT expressing ﬂies (Fig. 7C, compare
hDAT + AMPH versus hDAT R/W + AMPH). These data are consistent
with the reduced ability of AMPH to cause DA efﬂux in hDAT R/W
expressing cells. Basal locomotion of ﬂies expressing hDAT R/W did
not signiﬁcantly differ from hDAT expressing ﬂies.4. Discussion
Alterations in DA neurotransmission have been identiﬁed in several
neuropsychiatric disorders, including ASD (Nguyen et al., 2014; Cousins
et al., 2009; Seeman et al., 1990; Volkow et al., 2007). Recently, we
demonstrated that an ASD-associated hDAT de novo variant displays
dramatically altered DAT function, including constitutive reverse trans-
port of DA, which leads to hyperlocomotion (Hamilton et al., 2013).
Thus, we hypothesized that novel DAT variants (or variant in the
genes known to regulate the DAT) that affect DA neurotransmission
might contribute to the pathology and/or complications of ASD. We
identify and describe two independent gene variants that converge
mechanistically to disrupt DAT function and associated behaviors,
with distinct mechanisms regulating either STX1 phosphorylation or
STX1/DAT interaction.
Fig. 7. STX1 phosphorylation regulates AMPH-induced behaviors: (A) DAT knockout (KO) ﬂies demonstrate that AMPH-induced locomotor behavior is DAT-dependent. Locomotor activity
in response to vehicle (open symbols) or (1 mM) AMPH (ﬁlled symbols) in either wild-type (WT) (squares) or in DAT KO ﬂies (triangles). WT ﬂies exhibit a signiﬁcant AMPH-induced
increase in locomotion while DAT KO ﬂies do not exhibit this signiﬁcant increase (* = p b 0.05 for vehicle vs AMPH, two-way ANOVA followed by Bonferroni post-test; n = 5).
(B)Drosophilawere generated expressing a dominant-negative (DN) version of CK2α expressed speciﬁcally in dopaminergic neurons. Locomotor activity in response to vehicle (open sym-
bols) or AMPH (ﬁlled symbols) in either wild-type (WT) (squares) or in CK2 dominant negative ﬂies (CK2DN) (triangles). WT ﬂies exhibit a signiﬁcant increase in AMPH-induced locomo-
tionwhile CK2DN ﬂies donot (*=p b 0.05 for vehicle vs AMPH, two-wayANOVA followed by Bonferroni post-test; n=5). Inset: DAuptake in intact ﬂy brains in thepresence of 10 μMTBB
or vehicle. The absence of uptake in the dDAT KO ﬂy brains shows the dependence of DA uptake on the dDAT (*** = p b 0.0001 by one-way ANOVA followed by Newman–Keuls Multiple
Comparison Test; n=3). (C) hDATR/Wexpressingﬂies have blunted locomotor responses to AMPH. Changes in locomotionwere determined upon AMPHor vehicle exposure over 30min
and calculated as beam crosses (counts). AMPH (1mM) caused a signiﬁcant increase in locomotion in both hDAT ﬂies (p b 0.001 by one-way ANOVA followed by Newman–KeulsMultiple
Comparison Test; n= 24) and hDAT R/W ﬂies (p b 0.05 by one-way ANOVA followed byNewman–KeulsMultiple Comparison Test; n= 24). However, in hDATR/W ﬂies, AMPH exposure
led to a reduced increase in locomotion than in hDAT ﬂies (* = p b 0.05 by one-way ANOVA followed by Newman–Keuls Multiple Comparison Test; n = 24).
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of Ser14, a key residue involved in the functional regulation of STX1
(Khelashvili et al., 2012; Dubois et al., 2002). STX1 in this hypo-
phosphorylated state fails to support DAT-mediated reverse transport
of DA without inhibiting DA uptake function. Interestingly, in hDAT
cells expressing STX1 R/Q, we observe a signiﬁcantly increased Vmax of
DA uptake. In parallel experiments in mouse striatal slices, cleaving
STX1 with BoNT/C promotes a decrease in reverse transport of DA
with a trend towards increased DA uptake. These data suggest that
STX1 function asymmetrically regulates reverse transport of DA
and DA uptake. Therefore, to deﬁne how hypo-phosphorylation of
STX1 R/Q impairs DA reverse transport, we studied the regulatory
effects of CK2 function on DA efﬂux.
CK2 phosphorylates STX1 at Ser14 to regulate STX1 function and
protein interactions (Hirling and Scheller, 1996; Foletti et al., 2000;
Dubois et al., 2002). Here, we discovered that CK2-mediated phosphor-
ylation of STX1 at Ser14 increases the direct association between STX1
and the hDAT N-terminus. Consistently, pharmacological inhibition of
CK2 strongly reduces reverse transport of DA without altering DA
uptake. Thus, CK2 is a key player involved in DA efﬂux. It is possible
that this mechanism is important in a broader array of DA-associated
neuropsychiatric disorders, since the expression of CK2, as well as the
phosphorylation state of STX1 at Ser14, is decreased in post-mortem
brain tissue from patients with schizophrenia (Castillo et al., 2010;
Aksenova et al., 1991). To have a more complete understanding of
how genetic variants within the DA network discovered in ASD patients
alter behaviors, we translated our molecular discoveries in vivo. First,
we inhibited CK2 function by selectively expressing CK2DN speciﬁcally
in DA neurons of WT ﬂies. Drosophila expressing CK2DN exhibited a ro-
bust reduction in AMPH-induced hyperlocomotion as compared to WT
ﬂies. These data underscore the importance of CK2 function and STX1
phosphorylation in regulating behaviors sustained by reverse transport
of DA. Interestingly, inhibiting CK2 function did not regulate basal loco-
motion or DA uptake in intact Drosophila brains.
Parallel to STX1 R/Q, we found that the hDAT R/W variant displays
inhibited reverse transport of DA without impairments in uptake func-
tion. It is important to note that CK2 function, in addition to phosphor-
ylating STX1 at Ser14, also promotes STX1/DAT interactions. Here, we
show that hDAT R/W has reduced association with STX1, resulting in
reduced reverse transport of DA and DA-related behaviors. Drosophila
expressing hDAT R/W selectively in DA neurons demonstrate reduced
sensitivity to the psychomotor effects of AMPH. Interestingly, basal
locomotion remained unaltered in hDAT R/W ﬂies, indicating normal
DAT-mediated DA clearance as supported by our uptake data. These
data suggest that the phosphorylation state of STX1 at Ser14 and
STX1/DAT interaction asymmetrically regulate reverse transport of DA
and DAT-mediated uptake.
Mounting evidence demonstrates that reverse transport of DA and
associated behaviors can be promoted by changes in the association
between the N-terminus of DAT and STX1 (Binda et al., 2008). Addition-
ally, it has been suggested that reverse transport of DAmight participate
in shaping DA neurotransmission (Leviel, 2011). Here, we used AMPH
as a tool to induce reverse transport of DA to determine whether ASD-
associated variants disrupt this event. We show that AMPH promotes
phosphorylation of STX1 at Ser14 and, as a consequence, STX1/DAT
interaction to cause reverse transport of DA. Therefore, we felt that it
was important to demonstrate these discoveries at the level of a single
active site, the SCG bouton.
Several ASD-associated hDAT variants have now been found to
impact reverse transport of DA. The STX1 R/Q variant reported here
ablates AMPH-induced efﬂux similarly to hDAT R/W. Interestingly,
two other variants were previously found to cause dysregulation of
DA efﬂux, including a de novo DAT T356M variant and the recurrent
DAT A559V variant seen in two boys with ASD, as well as in individuals
with bipolar disorder and ADHD. These ﬁndings demonstrate diverging
mechanisms by which reverse transport of DA can be disrupted. Theyalign with other examples of neurodevelopmental risk emerging from
genetic variants causing opposite effects on gene expression or signal-
ing cascades (Sanders et al., 2011; Cook et al., 1997).
Here, we characterize two independent autism-associated variants
in the genes that encode STX1 and the DAT. We demonstrate that
each variant dramatically alters DAT function. We identify molecular
mechanisms that converge to inhibit reverse transport of DA and DA-
associated behaviors. The physiological importance of reverse transport
of DA has only recently emerged and remains incompletely understood.
However, deﬁning the molecular identity and the impact of these vari-
ants on DA efﬂux may further shape our understanding of the etiology
of ASD. Therefore, large genotyping studies aimed at uncovering other
variants of the hDAT and STX1A genes in ASD cases and matched con-
trols would be worthwhile.
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